Acne News and Research

Latest Acne News and Research

FDA approves Teva's Quartette tablets for prevention of pregnancy

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the prevention of pregnancy.

30 Mar 2013

No increased risk for inflammatory bowel disease with isotretinoin

Researchers report no link between isotretinoin use for the treatment of acne and increased risk for inflammatory bowel disease in women of reproductive age.

1 Mar 2013

Not all acne bacteria trigger pimples: Study

The bacteria that cause acne live on everyone's skin, yet one in five people is lucky enough to develop only an occasional pimple over a lifetime.

1 Mar 2013

XBiotech to enter biosimilar business

XBiotech, a privately held biotechnology company, announced today that it is entering the biosimilar business. The Company is launching its biosimilar business with development of two of the world's leading therapeutic antibodies, one an oncology and the other an anti-inflammatory product.

26 Feb 2013

Researchers use 3D printing and injectable gels to create bioengineered ears

Physicians at Weill Cornell Medical College and biomedical engineers at Cornell University have succeeded in building a facsimile of a living human ear that looks and acts like a natural ear. Researchers believe their bioengineering method will finally succeed in the long quest by scientists and physicians to provide normal looking "new" ears to thousands of children born with a congenital ear deformity.

22 Feb 2013

Isotretinoin does not increase risk of inflammatory bowel disease

Doctors should not be discouraged from prescribing isotretinoin to adolescents for inflammatory acne, according to a new study by Canadian and U.S. scientists showing the drug does not increase the risk of inflammatory bowel disease (IBD).

22 Feb 2013

Syneron dismisses U.S. patent infringement suit against Eclipse Aesthetics, EndyMed

Syneron Medical Ltd., the leading global aesthetic device company announced today, jointly with EndyMed Medical Ltd. and Eclipse Aesthetics, that Syneron has dismissed its United States patent infringement lawsuit against EndyMed and Eclipse Aesthetics relating to EndyMed's Fractional Skin Resurfacing Products.

22 Feb 2013

Medical nutrition therapy can play an important role in acne treatment

A study published in the Journal of the Academy of Nutrition and Dietetics has determined that there is increasing evidence of a connection between diet and acne, particularly from high glycemic load diets and dairy products, and that medical nutrition therapy (MNT) can play an important role in acne treatment.

20 Feb 2013

Solta Medical fourth quarter revenue increases 20% to $39.8 million

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced results for the fourth quarter ended December 31, 2012. Revenue for the fourth quarter was $39.8 million, an increase of $6.6 million, or 20%, as compared to the fourth quarter of 2011.

19 Feb 2013

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

14 Feb 2013

Everolimus treatment option for tuberous sclerosis patients

Researchers have shown that the immunosuppressant everolimus provides a potential new treatment option for patients with tuberous sclerosis and associated angiomyolipomas.

25 Jan 2013

NIH panel recommends name change for polycystic ovary syndrome

An independent panel convened by the National Institutes of Health has concluded that the name of a common hormone disorder in women, polycystic ovary syndrome (PCOS), causes confusion and is a barrier to research progress and effective patient care. The current name focuses on a criterion - ovarian cysts - which is neither necessary nor sufficient to diagnose the syndrome.

24 Jan 2013

People most often visit doctors because of skin issues, joint disorders and back pain

A new Mayo Clinic Proceedings study shows that people most often visit their health care providers because of skin issues, joint disorders and back pain. Findings may help researchers focus efforts to determine better ways to prevent and treat these conditions in large groups of people.

17 Jan 2013

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).

17 Jan 2013

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

16 Jan 2013

Dermatologists offer shaving tips for smooth results

Shaving can be a challenge for both men and women, especially in the winter. Yet getting a smooth shave with minimal irritation is possible.

9 Jan 2013

Combined oral contraceptives increase risk of blood clots in women with PCOS

Women with polycystic ovary syndrome (PCOS) who are taking combined oral contraceptives have a 2-fold risk of blood clots compared with women without the disorder who take contraceptives, states a study published in CMAJ (Canadian Medical Association Journal).

4 Dec 2012

Gateway Aesthetic announces addition of three new procedures

The Gateway Aesthetic Institute & Laser Center in Salt Lake City, Utah is pleased to announce the addition of three new procedures to its broad list of available services in the aesthetics' arena.

5 Nov 2012

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.

29 Oct 2012